Zepbound beats Wegovy for weight loss
Digest more
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.
Eli Lilly (NYSE:LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE:CVS) to limit access to the company’s popular weight loss drug, Zepbound, in favor of Novo Nordisk’s (NVO) rival drug,
If you’re prescribed Zepbound, your doctor or another healthcare professional will likely give you the first dose in their office. Then they’ll show you or someone else how to inject your ...
The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.
The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...
What To Know: WeightWatchers says this integration allows eligible self-pay patients, without insurance coverage, to receive prescriptions for Zepbound in single-dose vial form directly through ...